ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,06965
0,00%
Bitcoin
63.571,83
0,25%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT Arcutis Biotherapeutics Inc

8,31
-0,28 (-3,26%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,28 -3,26% 8,31 01:46:45
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
8,59 8,36 8,85 8,47 8,59
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
10.4.202414:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05.4.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01.4.202413:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28.3.202413:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11.3.202413:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10.3.202421:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09.3.202422:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06.3.202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04.3.202423:47EDGAR2Form 144 - Report of proposed sale of securities
04.3.202423:42EDGAR2Form 144 - Report of proposed sale of securities
04.3.202423:40EDGAR2Form 144 - Report of proposed sale of securities
04.3.202422:10EDGAR2Form 8-K - Current report
04.3.202422:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04.3.202414:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01.3.202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.2.202423:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29.2.202405:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28.2.202422:54EDGAR2Form 144 - Report of proposed sale of securities
28.2.202422:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28.2.202422:10EDGAR2Form 8-K - Current report
28.2.202422:10GLOBEArcutis Announces Proposed Public Offering
28.2.202422:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27.2.202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202413:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202413:44EDGAR2Form 8-K - Current report
27.2.202411:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16.2.202414:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16.2.202400:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:20EDGAR2Form 8-K - Current report
15.2.202422:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
13.2.202415:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08.2.202422:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.2.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
31.1.202423:22EDGAR2Form S-3 - Registration statement under Securities Act of..
31.1.202414:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29.1.202414:00GLOBEJournal of the American Academy of Dermatology Publishes..
24.1.202422:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
22.1.202414:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
17.1.202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.1.202410:00GLOBEMajority of Individuals with Atopic Dermatitis Improved with..

Kürzlich von Ihnen besucht

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten